Fig. 3

Specific gene expression, signaling-pathway patterns and in vivo drug response are correlated with BCL-2 dependence. A Associations between BH3 profile and in vivo drug response estimated from retrospective clinical data (lymphocyte drop rate) (Pearson’s correlation test). The lymphocyte drop rate was calculated by dividing the change in lymphocyte count (in millions) between the start and end of therapy by the duration of the therapy (in days) for each patient. B Example of significant correlations between BCL-2 dependence (reflected by ABT199, BAD or PUMA-induced CytC release) and mRNA expressions of PMAIP1 (NOXA), BCL2L11 (BIM), COX5A, LAG3, measured by RNA-seq. C Cancer hallmark pathways enrichment analysis for mRNAs correlated with BCL-2 dependence. Enrichment results passed 10% FDR control are shown. D A heatmap showing the mRNA expression of the genes (Blue to red bar indicates expression levels), both associated with BCL-2 dependence (Green bar indicates increasing BCL-2 dependence) and belong to the TNFα/NFκB-signaling pathway